Cardiol Therapeutics Secures Funding Through 2027 Amid Clinical Advancements

Cardiol Therapeutics strengthens finances with $31M, extends runway to Q4 2027, and advances Phase III pericarditis & Phase II myocarditis trials toward key 2026 data.

Cardiol Therapeutics has concluded its 2025 fiscal year from a position of financial and clinical strength. The company, which is pioneering treatments for inflammatory heart diseases with limited therapeutic options, has extended its operational runway while achieving key milestones in its clinical programs.

Financial Foundation Strengthened

A series of successful capital raises in October 2025 and January 2026 have solidified the firm's balance sheet. These financings injected a total of US$31 million into the company. Management states these funds are sufficient to finance operations through the fourth quarter of 2027. This financial cushion is designed to allow Cardiol to reach critical clinical data points without the immediate need for additional shareholder-dilutive funding.

The company's confidence is further bolstered by recently secured patents. These extend the protection for its lead drug candidates, CardiolRx™ and CRD-38, in the United States through to the year 2040.

Clinical Pipeline Progresses

On the clinical front, patient recruitment is advancing for the pivotal MAVERIC Phase III study in recurrent pericarditis. The company confirms that over 50% of the targeted 110 patients have now been enrolled across approximately 25 clinical sites in North America and Europe. The goal remains to complete full recruitment by the second quarter of 2026. This trial is evaluating the drug's ability to reduce pain and lower inflammation markers over a six-month period.

Concurrently, positive signals have emerged from the ARCHER Phase II study in acute myocarditis. Data published in the journal ESC Heart Failure indicates that the investigational therapy CardiolRx™ can reduce inflammation-driven heart tissue damage. A key finding was a significant reduction in left ventricular mass compared to the placebo group. This outcome holds particular importance, as acute myocarditis is a leading cause of sudden death in young adults under 35.

Market Reaction and Outlook

Despite these operational strides, the company's shares experienced a pullback in today's trading, declining 7.20% to €1.16. Market observers largely view this move as a technical correction following a substantial gain of approximately 37% over the previous month. With its Relative Strength Index (RSI) reading at 30, the equity is considered technically oversold in the short term.

The coming months will be crucial for Cardiol Therapeutics as it works to maintain the MAVERIC study's timeline toward a planned data readout in 2026. The extended financial runway provides the company with a stable platform to execute this strategy.